Apixaban (Eliquis) is a Factor Xa inhibitor direct oral anticoagulant (DOAC) used to prevent stroke in atrial fibrillation and treat deep vein thrombosis and pulmonary embolism. It requires no routine blood monitoring and has a lower rate of intracranial hemorrhage than warfarin. Common risks include bruising, nosebleeds, and major hemorrhage. Black box warnings cover premature discontinuation (which raises stroke and clot risk) and spinal hematoma with neuraxial anesthesia; the specific reversal agent is andexanet alfa (Andexxa).
Apixaban
Apixaban is a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa, a key enzyme in the coagulation cascade. Approved in the United States in 2012, it is one of the most prescribed anticoagulants in the world. Compared to warfarin, apixaban offers predictable pharmacokinetics, no routine monitoring requirement, fewer drug interactions, a lower rate of intracranial hemorrhage, and comparable or superior efficacy across its major indications.
Uses & FDA Indications
Apixaban is FDA-approved for: reducing stroke and systemic embolism risk in non-valvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); reduction in the risk of recurrent DVT and PE following initial therapy; and prevention of DVT following hip or knee replacement surgery.
These approvals are supported by the landmark ARISTOTLE trial (atrial fibrillation), and AMPLIFY trial (VTE treatment), which demonstrated superior or non-inferior outcomes compared to warfarin with a consistently lower rate of major bleeding, particularly intracranial hemorrhage.
In the ARISTOTLE trial comparing apixaban to warfarin in atrial fibrillation, apixaban was associated with a 21% relative reduction in stroke or systemic embolism, a 31% reduction in major bleeding, and an 11% reduction in all-cause mortality.
How It Works
Apixaban directly and selectively inhibits Factor Xa, a serine protease that sits at the convergence of the intrinsic and extrinsic coagulation pathways. Factor Xa catalyzes the conversion of prothrombin to thrombin; thrombin then converts fibrinogen to fibrin, the structural scaffold of blood clots. By blocking Factor Xa, apixaban interrupts clot formation without directly affecting platelet function or thrombin itself.
Unlike warfarin, apixaban does not require hepatic conversion or vitamin K cycling to exert its effect, and its action is direct and rapidly reversible. It is approximately 50% renally excreted and 50% eliminated via fecal routes through CYP3A4 metabolism and P-glycoprotein (P-gp) transport — clinically important because drugs affecting CYP3A4 or P-gp can significantly alter apixaban levels.
Apixaban does not require routine INR or other coagulation monitoring under normal clinical circumstances, which represents a major practical advantage over warfarin.
Side Effects
Common
- Bleeding — the primary risk of all anticoagulants; includes easy bruising, prolonged bleeding from wounds, nosebleeds, heavier menstrual periods
- Anemia (from occult bleeding)
- Nausea (uncommon)
Serious
- Major hemorrhage — GI bleeding, intracranial hemorrhage, retroperitoneal bleeding; lower rate than warfarin but clinically significant
- Spinal/epidural hematoma — when neuraxial anesthesia is used; potentially causes permanent paralysis
- Thrombosis upon abrupt discontinuation — premature stopping without adequate alternative anticoagulation significantly increases stroke or clot risk
- Hypersensitivity reactions — rare; anaphylaxis reported
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Strong dual CYP3A4 and P-gp inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) | Significantly increased apixaban exposure; major bleeding risk | High — dose reduction required; avoid if possible |
| Strong dual CYP3A4 and P-gp inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) | Significantly decreased apixaban levels; loss of anticoagulant effect and clot/stroke risk | High — avoid combination; consider alternative anticoagulant |
| Other anticoagulants (heparin, warfarin, rivaroxaban) | Additive bleeding risk | High — avoid concomitant use except during transitions |
| Antiplatelet agents (aspirin, clopidogrel, ticagrelor) | Additive bleeding risk through independent mechanism | High — combination should be prescribed only when clearly indicated; increases bleeding substantially |
| NSAIDs | Increased GI and systemic bleeding risk | Moderate–High — avoid chronic NSAID use |
| Selective serotonin reuptake inhibitors (SSRIs) | Modest additional bleeding risk through platelet inhibition | Moderate — monitor for unusual bruising or bleeding |
| Dronedarone / Verapamil (moderate P-gp/CYP3A4 inhibitors) | Moderate increase in apixaban levels | Moderate — dose adjustment may be considered |
Warnings & Contraindications
BLACK BOX WARNINGS: (1) Premature discontinuation increases the risk of thrombotic events. If apixaban must be stopped for reasons other than pathological bleeding, consider coverage with another anticoagulant. (2) Epidural or spinal hematomas — neuraxial anesthesia or spinal puncture in anticoagulated patients can result in long-term or permanent paralysis. Monitor for signs of neurological impairment.
Contraindications: Active pathological bleeding. Severe hypersensitivity reaction to apixaban. Prosthetic heart valves (not adequately studied; warfarin is required).
Renal impairment: Apixaban is partially renally eliminated. In patients with severe chronic kidney disease or those on dialysis, the pharmacokinetics change significantly. Use requires individualized assessment; apixaban is commonly used in patients with moderate CKD but requires careful consideration in end-stage renal disease.
Reversal: Andexanet alfa (Andexxa) is an FDA-approved specific reversal agent for apixaban and rivaroxaban in the setting of life-threatening or uncontrolled bleeding. Four-factor PCC is an alternative used in many centers. Unlike warfarin, apixaban cannot be reversed with vitamin K.
Switching anticoagulants: Transitioning between apixaban and other anticoagulants requires careful timing to minimize gaps in coverage and overlapping anticoagulant effect. Always follow prescriber guidance when switching.
Frequently Asked Questions
Do I need blood tests while taking apixaban?
Unlike warfarin, apixaban does not require routine INR or anticoagulant monitoring under normal circumstances. However, your prescriber will periodically assess renal and hepatic function, as declining kidney function can affect apixaban clearance. Standard blood counts may also be monitored to detect occult bleeding-related anemia.
What happens if I miss a dose of apixaban?
If a dose is missed, it should be taken as soon as remembered on the same day. Do not take two doses on the same day to make up for a missed dose. Because of its short half-life, missing doses intermittently can cause brief gaps in anticoagulant coverage — particularly important in patients with atrial fibrillation at high stroke risk.
Is apixaban safer than warfarin?
For most indications in appropriately selected patients, apixaban has demonstrated a lower rate of intracranial hemorrhage and total major bleeding compared to warfarin in large clinical trials. It also requires no dietary restrictions or routine monitoring. However, "safer" is individual — warfarin is still preferred for mechanical heart valves and certain patients with complex drug interactions or cost constraints.
Can apixaban be crushed or split?
Apixaban tablets can be crushed and mixed with water, juice, or applesauce for patients who cannot swallow tablets whole — this is supported by pharmacokinetic data and is referenced in the prescribing information. They can also be administered via nasogastric tube. Unlike some extended-release medications, the immediate-release apixaban tablet formulation does not require intact swallowing.
Need to identify an unknown pill? Use the free PillID tool.
Identify a Pill →